US FDA agrees changes for TroVax TRIST study
This article was originally published in Scrip
Executive Summary
The US FDAis to allow changes to the troubled Phase III TRIST study ofOxford BioMedica/Sanofi-Aventis's TroVax, which the UK biotech company hopes will help it identify patient groups which might benefit from the investigational therapeutic cancer vaccine.